Quality of Life Research
Latest Publications


TOTAL DOCUMENTS

4830
(FIVE YEARS 968)

H-INDEX

124
(FIVE YEARS 9)

Published By Springer-Verlag

1573-2649, 0962-9343

Author(s):  
Nemanja Aleksic ◽  
Svetozar Putnik ◽  
Sara Schroter ◽  
Vedrana Pavlovic ◽  
Uros Bumbasirevic ◽  
...  

Author(s):  
Marie Buzzi ◽  
Laetitia Minary ◽  
Yan Kestens ◽  
Nelly Agrinier ◽  
Laetitia Ricci ◽  
...  

Author(s):  
Monique M. Germone ◽  
Merlin Ariefdjohan ◽  
Marisa Stahl ◽  
Mary Shull ◽  
Pooja Mehta ◽  
...  

Author(s):  
Takuya Kawahara ◽  
Naruto Taira ◽  
Takeru Shiroiwa ◽  
Yasuhiro Hagiwara ◽  
Takashi Fukuda ◽  
...  

Abstract Purpose To establish minimal important differences (MIDs) for the European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) in patients with metastatic breast cancer. Methods The dataset was obtained from the SELECT BC-CONFIRM randomized clinical trial. Anchors obtained from patients (transition items) and clinicians (performance status) were used for anchor-based methods. Anchors obtained through 6 months after starting treatment were used for this analysis. Correlation coefficients of anchor and change in QLQ-C30 and effect size were used to qualify for estimating MIDs. Mean change method and generalized estimating equation were applied to estimate MIDs. Distribution-based methods were used for comparison. Results We analyzed a dataset of 154 metastatic breast cancer patients. MIDs were estimated in 8 of 15 scales of QLQ-C30. Estimated MIDs for within-group improvement varied from 7 to 15 and those for deterioration varied from − 7 to − 17. Estimated MIDs for between-group improvement varied from 5 to 11 and those for deterioration varied from − 5 to − 8 across QLQ-C30 scales. Patient-reported anchors were more susceptible to early changes in health status than clinician-reported anchors. Conclusion We provided the MIDs of the QLQ-C30 using both patient- and clinicians-reported anchors measured in a randomized trial of Japanese patients with metastatic breast cancer. We recommend patient-reported anchors for anchor-based estimation of MID. Our results can aid patients and clinicians, as well as researchers, in the interpretation of QLQ-C30.


Sign in / Sign up

Export Citation Format

Share Document